These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 17063130)
1. The lifetime cost of current human immunodeficiency virus care in the United States. Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. Hornberger J; Kilby JM; Wintfeld N; Green J AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916 [TBL] [Abstract][Full Text] [Related]
4. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893 [TBL] [Abstract][Full Text] [Related]
6. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y; AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655 [TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of combination antiretroviral therapy for HIV disease. Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720 [TBL] [Abstract][Full Text] [Related]
10. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. Krentz HB; Gill MJ HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856 [TBL] [Abstract][Full Text] [Related]
11. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients. Ruof J; Dusek A; DeSpirito M; Demasi RA Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127 [TBL] [Abstract][Full Text] [Related]
12. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961 [TBL] [Abstract][Full Text] [Related]
13. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423 [TBL] [Abstract][Full Text] [Related]
14. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M; N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625 [TBL] [Abstract][Full Text] [Related]
15. When to start antiretroviral therapy in resource-limited settings. Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E; Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982 [TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina. Rampaul M; Edun B; Gaskin M; Albrecht H; Weissman S South Med J; 2018 Jun; 111(6):355-358. PubMed ID: 29863227 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Brogan AJ; Talbird SE; Cohen C Value Health; 2011; 14(5):657-64. PubMed ID: 21839403 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. Bachmann MO AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768 [TBL] [Abstract][Full Text] [Related]